Manuscript ID eji.201343658 entitled "PD-1 modulates steady-state and infection-induced IL-10 production in vivo." which you submitted to the European Journal of Immunology has been reviewed. The comments of the referees are included at the bottom of this letter.
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resistance to the infection with Toxoplasma. There are some disconnects with the infection studies but a lack of insight into how PD-1 regulates IL-10 or evidence that it does this directly. Basically the authors are proposing that a basal defect that leads to more IL-10 is the cause of the increased susceptibility and it has nothing to do with the regulation of PD-1 during the infection -is that right? This is really a writing issue and putting their work in the context of the literature needs to be improved.
There are several studies that have looked at PD-1 in toxoplasmosis and, based on the Khan PNAS paper, the blockade of PD-1 has been reported to lead to increased CD8 effector function and improved control of T. gondii during the chronic phase of the infection i.e very different from the current submission.
At no point do the authors deal with this result head on. The Khan data do make a lot of sense in the context of "exhaustion" while the results here are very different.
It is also difficult to understand the conclusion that "we unveil a previously unrecognized role for IL-10 as a "fail-safe" system triggered in the absence of PD-1 signaling under steady-state conditions, which, antagonizes the rapid acquisition of type 1-dependent host protection against microbial pathogens". The point the authors are trying to convey is not clear.
Specific Comments
The focus of the manuscript is on T cells -but it seems like the STAG experiments are really about the innate response and it's a little hard to understand how this experiment informs the phenotype. Actuallythese data along with the IL-12 pretreatment results imply that this is largely an innate phenotype? Did the authors examine innate sources of IL-10? Figure 3B -what time was this and how many mice -and what did parasite burden look like in other sites? Figure 5D -treatment of WT mice with anti-PD-1 increases basal IL-10 -but anti-PD-L1 decreases and anti-PD-L2 has no effect? Did the authors try the combination of anti-PD-L1/L2? As is, these data sets are difficult to interpret. Can the authors show using an in vitro system that ligation or blockade of PD-1 affects T cell production of IL-10? This would be really key to understanding this phenotype.
Can they show IL-10 protein data to support the studies with the reporter mice for parasite specific IL-10?
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It is unclear from the data presented whether the PD-1 KO mice generate parasite specific T cells but they just don't make IFN-g or is there a major defect in the ability to even generate parasite specific T cells?
This seems like it would be important to know. Figure 2 -the authors need to be consistent with the symbol scheme that they use. The single panel survival curve in Figure 1 could also be incorporated into this figure.
Minor comments
There are some initial reports that some of the PD-1 KO mice develop spontaneous autoimmunity. Is this relevant to these mice?
First Revision -authors' response -11 July 2013
We are sincerely grateful to the reviewers and editor for their comments and interest in our manuscript.
We feel that the criticisms raised were valid and here we attempted to fully address all of them, our response follows:
Reviewer: 1 1. With the exception of a minor niggle in wanting to know whether macrophages and monocytes have raised IL-10 in PD1-/-mice or following administration of anti-PD1 mAb, I have no specific comments on the manuscript.
We agree with both reviewers about the potential role of myeloid cells (CD11c+CD11b+, CD11c-CD11b+ and CD11c+CD11b-) as a potential source of IL-10 hosts lacking PD1. Our results clearly indicated that no myeloid cell population acted as a source of increased IL-10 production in hosts devoid of PD1. This result is included in figures 6D and E and is discussed (page 10, line 23-page 9, lines 7-13).
Reviewer: 2 2. Basically the authors are proposing that a basal defect that leads to more IL-10 is the cause of the increased susceptibility and it has nothing to do with the regulation of PD-1 during the infection -is that right?
The reviewer is correct here. Our intention was to show that enhanced IL-10 production in naïve PD1-deficient (or Ab-depleted) hosts lead to suppressed protective immunity to infection with T. gondii.
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3. This is really a writing issue and putting their work in the context of the literature needs to be improved.
We thank the reviewer for bringing the need of more emphasis in the differences between our data in the context of the work published by Khan's group. In those manuscripts, the role of PD1 is assessed after infection, during late acute/early chronic phases and there is no data on PD1-deficient mice. While in our manuscript, the animals only received anti-PD1 treatment for 12 days prior to infection. The timing for treatment seems to be critical; our experiments are aiming at the baseline PD1 activity, while Khan's data is focused on activated effector CD8+ T cells. The other critical discrepancy that might be derived from the context in which PD1 is neutralized (i.e. before vs. after infection) is that we did not see any effect of PDL1 or PDL2 in inducing increased IL-10 production. This is now included in the discussion of the manuscript (page 12, lines 9-19).
4. It is also difficult to understand the conclusion that "we unveil a previously unrecognized role for IL-10 as a "fail-safe" system triggered in the absence of PD-1 signaling under steady-state conditions, which, antagonizes the rapid acquisition of type 1-dependent host protection against microbial pathogens". The point the authors are trying to convey is not clear.
We now expanded on the concept of redundancy between PD1 and IL-10 in the discussion (page 13, lines 7-12).
5. The focus of the manuscript is on T cells -but it seems like the STAG experiments are really about the innate response and it's a little hard to understand how this experiment informs the phenotype. Actuallythese data along with the IL-12 pretreatment results imply that this is largely an innate phenotype? Did the authors examine innate sources of IL-10?
We think that the conditioning of the innate system with increased IL-10 production led to susceptibility to infection, since there is significant reduction in IL-12 and subsequent, IFN-gamma production. We agree with the reviewer with regard to the importance of including results showing innate sources of IL-10, as discussed above in question#1.
6. Figure 3B The data shown is from day 20 after infection and is the mean+/-SEM of 12 mice. The parasite burden was evaluated in the spleen and liver at 15 days after infection by PCR. The results are now shown in Figure 3D .
7. Figure 5D -treatment of WT mice with anti-PD-1 increases basal IL-10 -but anti-PD-L1 decreases and anti-PD-L2 has no effect? Did the authors try the combination of anti-PD-L1/L2? As is, these data sets are difficult to interpret.
Our data shows single antibody treatment (anti-PDL1 vs anti-PDL2) in WT mice and anti-PDL1 treatment in PDL2-deficient mice. We expanded the description of the results presented (page 13, lines 7-12).
8. Figure 6 -the authors need to show what happens to the levels of IL-10 when they deplete CD4 or CD8
T cells. The current model would suggest that depleting CD4+ T cells would lead to improved survival and better control of the parasite and this should be performed.
We agree with the reviewer, we now included the results showing that CD4/CD8 depletion reduced the baseline IL-10 production in PD1-deficient hosts and allowed for enhanced IL-12 production when animals were challenged with STAg in vivo (shown in figure 6F-G) . However, CD4/CD8 depletion affects protective immune response to infection, as these cells are critical sources of IFN-γ. Therefore, the effects of CD4/CD8 depletion cannot be examined in the context of infection with T. gondii.
9. Can the authors show using an in vitro system that ligation or blockade of PD-1 affects T cell production of IL-10? This would be really key to understanding this phenotype.
The increase in IL-10 production cannot be replicated in vitro. Our attempts at reproducing the in vivo conditions in which PD1-KO mice produce more IL-10 failed. The underlying hypothesis is that a systemic effect of the absence of PD1 induces IL-10, however the nature of this signal is not clear at the moment, as it cannot be replicated by PDL1 or PDL2 and it goes beyond the scope of this manuscript.
10. Can they show IL-10 protein data to support the studies with the reporter mice for parasite specific IL-10?
Yes, the results are now included in Figure 6C .
11. It is unclear from the data presented whether the PD-1 KO mice generate parasite specific T cells but they just don't make IFN-g or is there a major defect in the ability to even generate parasite specific T cells? This seems like it would be important to know. We apologize for this error, it is now corrected.
13. There are some initial reports that some of the PD-1 KO mice develop spontaneous autoimmunity. Is this relevant to these mice? Not at this stage, autoimmunity is detected in males only after 12-18 months of age. All experiments were performed with 6-10 weeks-old females. Although the referee and editor have recommended publication, some revisions to your manuscript have been requested. You will see in particular that the referee feels that some of the statements you have stuck to in your paper are not supported by data, and thinks that you should either provide the data, or tone down your arguments. You should know that while the Editor at this stage does not feel that extra data are warranted, we do feel that the manuscript would benefit from a re-write to focus and clarify your arguments. More details can be found below in the comments and the edited text file.
Second Editorial
You should also pay close attention to the editorial comments included below. *In particular, please edit your figure legends to follow Journal standards as outlined in the editorial comments. Failure to do this will result in delays in the re-review process.* If the revision of the paper is expected to take more than three months, please inform the editorial office.
Revisions taking longer than six months may be assessed by new referees to ensure the relevance and timeliness of the data.
Once again, thank you for submitting your manuscript to European Journal of Immunology. We look forward to receiving your revision.
